Employees: 1,332
Size Lanzhou Foci Pharmaceutical (002644.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $548M, the 3471st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥7.17 on 18 Nov 2026.
Performance Over six months the shares fell 8.7%, against -22.9% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue grew 6.1% over the last twelve months (peer median -3.0%); the operating margin is 6.2% (peer median 12.2%).
Valuation It trades at 3.3× enterprise value to sales against a peer median of 2.9× (8th most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 15% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.7 points below its cost of capital (8.7% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥942M | CN¥909M | CN¥966M | CN¥1.16B | CN¥1.04B |
| Revenue growth | — | -6% | -17% | +12% | — |
| Gross profit | CN¥347M | CN¥284M | CN¥266M | CN¥337M | CN¥284M |
| EBITDA | n/a | CN¥98.5M | CN¥95.5M | CN¥122M | CN¥115M |
| Net income | CN¥61.8M | CN¥49.2M | CN¥60.1M | CN¥67.2M | CN¥109M |
| Free cash flow | CN¥248M | CN¥165M | CN¥26.9M | CN¥45.0M | CN¥45.8M |
| Capital expenditure | CN¥35.2M | CN¥18.5M | CN¥13.3M | CN¥22.5M | CN¥41.5M |
| Total debt | CN¥75.9M | CN¥98.4M | CN¥88.4M | CN¥80.1M | CN¥57.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002644.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.2% | -10.8% | 10th highest of 21 |
| 6-month return | -8.7% | -22.9% | 6th highest of 21 |
| Distance from 52-week high | -34.9% | -46.5% | 4th highest of 21 |
| Revenue growth (TTM) | +6.1% | -3.0% | 7th highest of 19 |
| Operating margin | 6.2% | 12.2% | 10th lowest of 21 |
| EV / Sales | 3.3× | 2.9× | 8th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 15.4% | 1.8% | 3rd most demanding of 13 |
| Growth delivered (Del g) | +6.5% | +7.0% | 6th lowest of 12 |
| Hurdle (Req g minus delivered) | +8.9 pp | -1.4 pp | 2nd most demanding of 12 |
| ROIC minus cost of capital | -2.7 pp | -0.1 pp | 6th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Lanzhou Foci Pharmaceutical 002644.SZ | China | $548M | -9% | +6% | 6% | 3.3× | 15.4% | +6.5% |
| Hunan Hansen Pharmaceutical 002412.SZ | China | $532M | -2% | -4% | 21% | 3.0× | 1.4% | +7.0% |
| ArriVent BioPharma AVBP | United States | $564M | -60% | n/a | -3,620% | 34.2× | n/a | n/a |
| Hangzhou Minsheng Healthcare 301507.SZ | China | $583M | -23% | +21% | 11% | 3.8× | 19.1% | +12.1% |
| ABA Chemicals 300261.SZ | China | $592M | -26% | -16% | -23% | 4.9× | n/a | n/a |
| CK Life Sciences International (Holdings) 0775.HK | Hong Kong | $613M | -30% | 0% | 0% | 2.0× | n/a | n/a |
| Lionco Pharmaceutical 603669.SS | China | $474M | +4% | -6% | -17% | 8.4× | n/a | n/a |
| Shanxi Zhendong Pharmaceutical 300158.SZ | China | $641M | -22% | -28% | -25% | 1.8× | n/a | n/a |
| Myung in Pharm 317450.KS | South Korea | $466M | -20% | +7% | 35% | 0.7× | n/a | n/a |
| Brother Enterprises 002562.SZ | China | $668M | -33% | +8% | 4% | 1.5× | 4.0% | +13.5% |
| Shanghai Kaibao Pharmaceutical 300039.SZ | China | $703M | -20% | -14% | 22% | 3.4× | 0.4% | +4.8% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $718M | -36% | -12% | 3% | 2.2× | 2.1% | -1.3% |
| Tibet Aim Pharm 002826.SZ | China | $407M | -22% | +13% | 14% | 2.9× | 0.4% | +1.0% |
| Sirio Pharma 300791.SZ | China | $759M | -6% | -9% | 1% | 1.5× | 14.1% | +15.6% |
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $760M | -8% | -18% | 25% | n/a | n/a | n/a |
| Boiron BOI.PA | France | $367M | -31% | -2% | 5% | 0.6× | -0.8% | -0.5% |
| TSI 603262.SS | China | $842M | -46% | +3% | 14% | 4.6× | 24.3% | +13.4% |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $856M | -34% | +30% | 15% | 2.1× | n/a | n/a |
| Daiken Biomedical 7780.TW | Taiwan | $342M | -19% | n/a | 18% | 3.0× | -1.6% | n/a |
| Grape King Bio 1707.TW | Taiwan | $342M | -27% | -5% | 19% | 1.0× | -17.2% | +2.3% |
| PharmaNutra PHN.MI | Italy | $922M | +2% | +17% | 22% | 5.6× | 4.7% | +18.5% |